Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

a medicine for asthma

A drug and No. 1 technology, applied in the field of medicine, can solve the problems of inconspicuous therapeutic effect, low cure rate, palliative treatment and not the root cause, and achieve good non-specific immune effect and remarkable therapeutic effect

Inactive Publication Date: 2016-02-17
解玉启
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hormone injection therapy can only relieve the clinical symptoms of some patients. The administration method of this therapy is not easy to master, and the curative effect is not ideal. Therapy has been used for a long time (it has been used for more than one hundred years), but it still cannot completely cure asthma. Because the treatment period of this therapy is too long (the treatment period generally takes 3-5 years), it is difficult for patients to persist. The cure rate of the therapy is low, and most patients lose confidence because of the ineffective treatment, give up halfway, and give up the treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0042] A medicine for treating asthma, characterized in that the medicine is composed of No. 1 medicine, No. 2 medicine and No. 3 medicine; the ingredients of No. 1 medicine are: dead BCG, potato starch, aminophylline, ketotifen , Kekemin, levamisole, bromhexine, green tea, a total of eight kinds, the weight ratio is: dead BCG 0.016g, potato starch 1.071g, aminophylline 0.3g, ketotifen 0.001g, Kekemin 0.005g , levamisole 0.025g; bromhexine 0.03g, green tea 0.8g; the ingredients of No. g; the composition of No. 3 drug is: Codonopsis pilosula, Radix Astragali, Epimedium, and Gypsum, totally four kinds, and its weight ratio is: Codonopsis 1.2g, Astragalus 1.2g, Epimedium 0.3g, and Gypsum 0.4g;

[0043] The preparation method is as follows:

[0044] 1. Making No. 1 drug

[0045] 1. Making dead BCG powder

[0046] Take 0.016g of dead BCG according to the above weight ratio, then inject 0.5-1ml of distilled water into 0.016g of dead BCG, dissolve and form a mixed solution, mix th...

example 1

[0058] Example 1: Patient Fu Dongsheng, male, 52 years old, worker at Qinhuangdao Yaohua 156 Factory, suffered from exogenous allergic bronchial asthma for 12 years, was diagnosed and treated in Beijing, Henan and other places, and underwent various treatments including desensitization therapy Method, the treatment is ineffective, and came here to seek medical advice in 2000. After ten courses of treatment using the medicine of the present invention, it was radically cured, and the drug withdrawal was observed so far, and never recurred.

example 2

[0059] Example 2: Patient Xu Yurong, female, 52 years old, cadre of Qinhuangdao Yaohua 156 Factory, suffered from mixed allergic bronchial asthma for four years, had been diagnosed and treated in many big cities, but had no obvious effect. Six courses of drug therapy have been completely cured, and no recurrence has been seen in twelve years since the drug was stopped.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a special-effect drug for treating asthma, which is composed of a drug I, a drug II and a drug III; the drug I comprises the following components by weight: 0.016g of dead bacillus calmette guerin vaccine, 1.071g of potato starch, 0.3g of aminophylline, 0.001g of ketotifen, 0.005g of dioxopromethazine, 0.025g of levomisole, 0.03g of bromhexine and 0.8g of green tea; the drug II comprises the following components by weight: 1.4g of fructus schisandrae, 1.4g of astragalus and 0.3g of cinnamon; and the drug IIT comprises the following components by weight: 1.2g of radix codonopsis, 1.2g of astragalus, 0.3g of epimedium and 0.4g of gypsum. The special-effect drug disclosed by the invention is prepared on the basis of combination of Chinese and western medicine sciences, has remarkable treatment effect, and treats both symptoms and root causes.

Description

technical field [0001] The invention relates to a medicine for treating asthma, belonging to the technical field of medicine. Background technique [0002] Asthma, also known as allergic bronchial asthma, is a worldwide frequently-occurring disease, listed by the World Health Organization as one of the four major chronic diseases, and has a very high mortality rate (the death rate occupies the fourth place among all diseases, and Taiwan's famous singer Teresa Teng died of an asthma attack). In recent years, the proportion of children among asthmatic patients has shown an upward trend (the incidence rate is 50%), which has aroused great concern from insiders. [0003] Studies have shown that asthma is generally a chronic airway inflammation caused by the participation of eosinophils, mast cells, T cells and other cells and cell components. This inflammation leads to airway hyperresponsiveness and narrowing of the airways, which manifests as recurrent attacks, wheezing, dysp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/82A61K36/57A61K36/481A61P11/06A61K31/137A61K31/429A61K31/4535A61K31/522A61K31/5415A61K33/06A61K35/74
Inventor 解玉启
Owner 解玉启
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products